This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks Insiders Are Loading Up On

Ziopharm Oncology

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Another stock that insiders are buying up is biopharmaceutical player Ziopharm Oncology (ZIOP), which is seeking to develop and commercialize a diverse portfolio of in-licensed cancer drugs that can address unmet medical needs. Insiders are buying into strength here since this stock is up over 16% in 2012.

Ziopharm Oncology has a market cap of $348 million and an enterprise value of $228 million. This stock trades at a rich valuation, with a price-to-sales of 744.27 and a price-to-book of 4.13. Its estimated growth rate for this year is -53.5%, and for next year it's pegged at -2.8%. This is a cash-rich company, since the total cash position on its balance sheet is $118.93 and its total debt is zero.

A director and beneficial owner just bought 1,923,075 shares, or around $10 million worth of stock, at $5.20 per share.

From a technical standpoint, ZIOP is currently trading above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently found big buying support at around $4.10 to $4.15 a share, and since then it has rallied back above its 50-day moving average toward its current price of $5.30 a share. This stock is now setting up to trigger a big breakout if it can manage to clear some near-term overhead resistance levels. If you're bullish on ZIOP, then one could be a buyer once it triggers a breakout trade above $5.32 to $5.34 (200-day) with strong volume. Look for volume that's near or above its three-month average action of 498,685 shares. At last check, volume today has already surpassed that level and the stock is trading at $5.25 a share. If that breakout triggers either today or in the near future, then traders should look for $5.90 or higher for ZIOP.

ZIOP shows up on a list of 13 Stocks Bought and Sold by Hedge Funds for the most recently reported quarter.

3 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,055.29 -15.93 -0.09%
S&P 500 1,975.65 -2.15 -0.11%
NASDAQ 4,496.5090 -9.3430 -0.21%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs